Combination Therapy Shows Promise in Prostate Cancer
NEW YORK (Reuters Health) – The combination of high-dose salvage pelvic radiotherapy and six months of androgen-deprivation therapy (ADT) shows
Read more
Combo Disappoints in Metastatic Prostate Cancer
Combining the tyrosine kinase inhibitor saracatinib with docetaxel does not benefit patients with metastatic, castration-resistant prostate cancer (mCRPC), according to
Read more
New Screening: MRI Scans to discover prostate cancer earlier and more accurately
MRI instead of PSA A new method for the diagnosis of prostate cancer is tested. The promising Test could be
Read more